卡维地洛和美托洛尔治疗慢性充血性心力衰竭疗效及安全性

【摘要】 目的:探讨卡维地洛与关托洛尔治疗慢性充血性心力衰竭的疗效及安全性是否有差异。方法:将104例慢性心力衰竭患者随机分为两组,应用卡维地洛为观察组和应用美托洛尔为对照组,对比两治疗前后的心功能、左室射血分数、左室收缩末内径、左室舒张未内径、血压、心率及不良反应。结果:卡维地洛治疗组治疗慢性充血性心力衰竭总有效率94.4%,美托洛尔组84.0%,差异有显著性(P<0.05);关托洛尔组引起的心衰加重房室传导阻滞、血糖增高病例比卡维地洛组多见。结论:卡维地洛治疗慢性充血性心力衰竭总的疗效要好于美托洛尔且不良反应少,对慢性充血性心力衰竭应用β受体阻滞药宜首选卡维地洛。更多还原

【Abstract】 Objective:To evaluate the efficacy and safety of carvedilol and metoprolol in the treatment of chronic heart failure.Methods:104 patients were randomly divided into carvedilol group and metoprolol group.The cardiac function,blood pressure and side effects were compared between two groups before and after the treatment.Results:The total effective rate was 94.4% in carvedilol group and 84.0% in metoprolol group,the difference was significant.More atrioventricular block and high blood sugar were found in carvedilol group.Conclusion:carvedilol is superior to metoprolol in the treatment of chronic congestive heart failure.更多还原